Vyleesi (Bremelanotide) in Adolescents Ages 12 to 17: What the Off-Label Evidence Actually Shows

What Is Bremelanotide and Why Does Age Matter?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist developed by AMAG Pharmaceuticals and approved by the FDA on August 21, 2019 under the brand name Vyleesi. The approved indication is acquired, generalized HSDD in premenopausal adult women [1]. The drug works at the central nervous system level, binding MC4R to modulate dopaminergic pathways associated with sexual desire. That mechanism is specifically tied to adult neuroendocrine architecture.

Adolescent neurodevelopment is a distinct biological state. The dopaminergic reward circuitry, hypothalamic-pituitary-gonadal (HPG) axis, and melanocortin signaling networks are all actively maturing between ages 12 and 17 [2]. Introducing a potent MC4R agonist during this window carries theoretical developmental risks that have never been studied in human trials.

The FDA Approval Pathway

The FDA granted approval based on two key Phase 3 trials: RECONNECT Study 1 and RECONNECT Study 2. Both trials enrolled exclusively premenopausal women aged 18 and older [3]. Neither protocol included a pediatric cohort, and no pediatric study requirement was issued under the Pediatric Research Equity Act (PREA) because HSDD is not a condition the FDA has formally defined in patients under 18 [1].

The prescribing label carries no pediatric dosing section. Where no data exist, the label states only: "Safety and effectiveness in pediatric patients have not been established" [1].

What PREA and BPCA Mean for This Drug

Under PREA (21 U.S.C. 355a), sponsors must conduct pediatric studies for drugs that may be used in a substantial population of pediatric patients. The FDA issued no such requirement for bremelanotide, reflecting the agency's position that the approved indication does not apply to patients under 18 [4]. The Best Pharmaceuticals for Children Act (BPCA) offers incentives for voluntary pediatric study, but no sponsor has pursued this pathway for bremelanotide as of the date of this article [4].

The Pharmacology of Bremelanotide in the Context of Adolescent Physiology

Bremelanotide's half-life is approximately 2.7 hours. It achieves peak plasma concentration (Cmax) roughly 1 hour after subcutaneous injection in adult subjects [1]. What is unknown is how adolescent pharmacokinetics might differ, because body composition, renal clearance rates, and hepatic CYP enzyme activity change substantially through puberty [5].

Melanocortin Receptor Signaling During Puberty

MC4R is expressed throughout the hypothalamus and limbic system. In animal models, melanocortin signaling has documented roles in pubertal timing and gonadotropin release [6]. A study published in the Journal of Clinical Endocrinology and Metabolism found that central melanocortin tone modulates luteinizing hormone (LH) pulsatility in ovariectomized sheep, suggesting a direct link between MC4R activation and HPG axis function [7]. Whether exogenous MC4R agonism during human puberty could perturb LH or FSH secretion is not established in any human data.

Cardiovascular Considerations in Developing Patients

The Vyleesi prescribing label documents a mean transient blood pressure increase of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking at about 4 hours post-dose and resolving within 12 hours [1]. In adults with known cardiovascular disease, bremelanotide is not recommended. Adolescents, while generally cardiovascular-healthy, include subpopulations with congenital heart conditions, primary hypertension, and obesity-related cardiometabolic risk. The interaction of bremelanotide's hemodynamic profile with an adolescent cardiovascular system that may have undiagnosed anomalies has not been studied [8].

Drug Interactions Relevant to Adolescent Prescribing

Bremelanotide can delay gastric emptying, reducing oral drug absorption for medications taken within 1 hour of injection [1]. Adolescents are more likely than adults to take oral contraceptives, antidepressants, or stimulant medications. The FDA label specifically warns that drugs with narrow therapeutic indices whose absorption could be affected include naltrexone oral formulations [1]. Clinicians considering any off-label use in this population would need a complete medication reconciliation before any trial of the drug.

Evidence (or the Absence of It): What the Clinical Trial Record Shows

The absence of evidence is itself the clinical data. A search of ClinicalTrials.gov for "bremelanotide" returns no completed, active, or recruiting trials that include patients under 18 [9]. PubMed returns zero peer-reviewed case reports or observational studies describing bremelanotide administration to human adolescents [10].

The RECONNECT Trials: Adult-Only Data

The two RECONNECT Phase 3 trials (NCT02333071, NCT02338960) together enrolled 1,267 premenopausal adult women with HSDD [3]. Primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score. At 24 weeks, bremelanotide produced a statistically significant improvement in both measures compared with placebo (P<0.001) [3]. Mean age of enrolled subjects was 38.5 years. The youngest enrolled subject was 18. There are no subgroup analyses for any age below 18 because none were enrolled.

What the Nausea Profile Means for Adolescents

In the RECONNECT trials, nausea was reported by approximately 40% of bremelanotide-treated subjects versus 8% of placebo subjects [3]. Nausea was the primary reason for discontinuation in 8.1% of treated patients [1]. Adolescents may be more susceptible to nausea-related side effects from melanocortin agonism based on animal pharmacology data showing MC4R involvement in emesis pathways [11]. No dose-finding studies for adolescents exist to determine whether 1.75 mg (the only approved adult dose) would be appropriate, too high, or too low for patients in this age group.

Hyperpigmentation: A Cosmetically Significant Concern for Teens

Bremelanotide activates MC1R in addition to MC4R. MC1R stimulation increases melanogenesis. The prescribing label reports focal hyperpigmentation of the face, gums, and breasts in 1% of subjects in the Phase 3 trials, with some cases persisting or worsening with repeated dosing and taking up to 20 weeks to resolve after discontinuation [1]. For adolescents, who are already navigating significant body image concerns, persistent facial hyperpigmentation is not a trivial adverse effect. Dermatologic counseling would be mandatory for any off-label use in this group.

Why HSDD Diagnosis in Adolescents Is Itself Contested

HSDD as defined in the DSM-5 and the International Classification of Diseases (ICD-11) applies as a diagnosable condition in adults [12]. In adolescents, low sexual desire may reflect normal developmental variation, depression, trauma history, relationship context, hormonal contraceptive use, or emerging identity factors rather than a primary biologic disorder of desire [13].

DSM-5 Diagnostic Criteria and Age

The DSM-5 reconfigured female sexual interest/arousal disorder (FSIAD) to account for responsive rather than spontaneous desire patterns [12]. The diagnostic criteria explicitly require clinicians to consider developmental context. A 14-year-old with low sexual desire does not meet criteria for FSIAD in the same way a 38-year-old married woman reporting sustained distress over a multiyear period does. The diagnosis requires persistence of at least 6 months and significant personal distress, but developmental norms for adolescent desire are not well characterized in the literature.

Non-Pharmacologic First-Line Treatments

The American College of Obstetricians and Gynecologists (ACOG) and the International Society for the Study of Women's Sexual Health (ISSWSH) both recommend cognitive behavioral therapy, sex therapy, and psychoeducation as first-line treatment for sexual dysfunction in women, particularly younger patients [14]. These recommendations do not contemplate pharmacologic intervention in adolescents for this indication. A 2021 ISSWSH process-of-care consensus recommended that clinicians rule out relationship distress, trauma, and mood disorders before considering any pharmacologic approach, regardless of patient age [15].

Regulatory and Ethical Framework for Off-Label Use in Minors

Off-label prescribing is legal and common in adult medicine. In pediatric patients, it carries additional ethical and regulatory weight. The American Academy of Pediatrics (AAP) has published guidance stating that off-label prescribing in minors requires particularly careful benefit-risk analysis, documentation of the clinical rationale, and informed consent from both the minor and a guardian when the minor is under 18 [16].

Informed Consent Considerations

For bremelanotide specifically, the informed consent discussion would need to cover the following points: the complete absence of safety or efficacy data in patients under 18; the theoretical risk of HPG axis disruption; the documented cardiovascular blood pressure effect; the 40% nausea incidence; and the risk of persistent facial hyperpigmentation [1]. The AAP guidance notes that when no pediatric data exist and adult data cannot be extrapolated due to physiologic differences, the threshold for proceeding with off-label use should be very high [16].

Liability Exposure for Prescribers

Prescribers who administer bremelanotide to patients under 18 without a documented, compelling clinical rationale and thorough informed consent process expose themselves to significant medicolegal risk. The FDA label's explicit statement that "safety and effectiveness in pediatric patients have not been established" functions as a direct notice to prescribers that they are operating outside the studied and approved population [1].

A Clinical Decision Framework for Rare Exceptional Cases

In the extraordinarily rare scenario where a clinician believes a trial of bremelanotide in a 16- or 17-year-old might be warranted (for example, a post-pubertal patient with a documented, treatment-refractory desire disorder causing severe distress after exhausting all guideline-recommended non-pharmacologic options), the following steps should precede any prescription:

1. Confirm post-pubertal status and Tanner Stage V development, since the HPG axis disruption risk is theoretically lower once pubertal maturation is complete.
2. Obtain cardiology clearance, including blood pressure baseline and electrocardiogram.
3. Complete a full medication reconciliation with attention to oral contraceptives, SSRIs, SNRIs, stimulants, and any drug with a narrow therapeutic index.
4. Assess for hyperpigmentation risk factors, including Fitzpatrick skin types IV, VI, which carry higher baseline melanization risk.
5. Obtain written informed consent from the patient and a legal guardian, documenting the absence of pediatric trial data.
6. File an MedWatch adverse event report with the FDA if the drug is used and any adverse event occurs, to contribute to the post-market safety database [17].

This framework does not constitute a recommendation to prescribe. It describes minimum precautions for the rare prescriber who proceeds after exhausting all other options.

What Adolescents and Families Should Know

Adolescents searching for help with low sexual desire deserve honest, compassionate clinical guidance rather than off-label medication without evidence. The most common causes of diminished desire in this age group are treatable without pharmacology.

Conditions to Rule Out First

A complete workup for an adolescent presenting with low sexual desire should include thyroid function tests (TSH, free T4), prolactin levels, total and free testosterone, and screening for depression and anxiety using validated tools such as the PHQ-9 and GAD-7 [18]. Hormonal contraceptive-associated sexual dysfunction is well documented: a 2016 study in JAMA Internal Medicine (N=1,006,540 Danish women) found hormonal contraceptive use was associated with a statistically significant increase in antidepressant use, which may confound desire assessments [19]. Switching contraceptive method or formulation resolves desire complaints in a meaningful proportion of cases without any additional intervention.

Mental Health and Trauma Screening

Adverse childhood experiences (ACEs) are strongly associated with sexual dysfunction in young women. A 2019 systematic review in the Journal of Sexual Medicine identified ACE scores as a significant predictor of sexual dysfunction in women aged 18 to 35, with the caveat that most studies did not extend enrollment below 18 [20]. Clinicians should screen for trauma history using a validated tool before any pharmacologic discussion.

When to Refer

Adolescents with persistent, distressing low desire should be referred to a certified sex therapist or adolescent psychiatrist before pharmacologic options are discussed. The Society for Sex Therapy and Research (SSTAR) maintains a therapist locator. CBT-based interventions have demonstrated efficacy in adult populations with FSIAD; extrapolation to adolescents is reasonable given the low risk profile of behavioral interventions compared with pharmacology [21].

Summary of Key Clinical Points

Bremelanotide is not approved for patients under 18. No human trial data exist for this age group. The drug's mechanism involves active neuroendocrine pathways that are undergoing maturation during adolescence, creating a plausible theoretical concern about HPG axis effects that cannot currently be characterized. Documented adult adverse effects, including a 40% nausea rate, transient blood pressure elevation, and persistent hyperpigmentation, are meaningful in any population but carry particular weight in patients whose long-term developmental trajectory is still unfolding.

Clinicians who receive requests for bremelanotide from or on behalf of adolescent patients should redirect the clinical encounter toward thorough diagnostic workup and evidence-supported non-pharmacologic treatment. Any prescriber who proceeds with off-label use must file a MedWatch report for any adverse event observed, contributing to the post-market surveillance database that remains the only mechanism by which pediatric safety signals for this drug could currently be detected [17].